Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01942629

Enrollment

300

Registered

2013-09-16

Start date

2013-10-31

Completion date

2015-12-31

Last updated

2013-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Ductal Adenocarcinoma

Keywords

prognostic markers,Pancreatic ductal adenocarcinoma

Brief summary

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis. Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma. In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

Interventions

OTHERtheir will be no intervention in any of the groups, the study is retrospective

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma. * Available histopathological diagnosis of the malignancy.

Exclusion criteria

* Patients with inoperable tumors. * Patients with second primary tumor. * Patients with pathological blocks not enough for future slicing.

Design outcomes

Primary

Measure	Time frame	Description
5 year overall survival	5 years	if the patient is alive or dead 5 years following the treatment

Secondary

Measure	Time frame	Description
recurrence free survival	5 years	the recurrence of the disease within 5 years from the treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026